Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug aims to tame overactive thyroid in Graves' disease

NCT ID NCT07682896

Disease control Sponsor: Yarrow Bioscience, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 06, 2026 · Last updated Sep 04, 2026 · Updated 4 times

Summary

This phase 2 trial tests an experimental drug called YB-101 in people with Graves' disease, an autoimmune condition that causes an overactive thyroid. The study will see if YB-101 can help normalize thyroid hormone levels and allow patients to stop taking anti-thyroid medications. Participants receive either YB-101 or a placebo injection over 24 weeks, with safety and effectiveness monitored closely.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
YB-101
What this could lead to
If successful, YB-101 could offer a new way to control thyroid function in Graves' disease, potentially reducing the need for anti-thyroid drugs.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to everyone. The drug may cause side effects or fail to improve thyroid function.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 232 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Sep 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Have a documented diagnosis of Graves' Disease confirmed by the presence of thyroid-stimulating hormone receptor antibodies (TRAbs) by medical history or screening laboratory assessment * Have a pre-existing diagnosis of TED or, conversely, no evidence of TED at the ophthalmological examination performed during screening * Additional inclusion criteria are defined in the protocol Exclusion Criteria: * Previously treated with radioactive iodine (RAI) therapy or underwent total thyroidectomy * Received any dose of levothyroxine, desiccated thyroid extract, or T3 within 6 weeks before screening * Current treatment with teprotumumab or exposure to teprotumumab within 15 weeks prior to screening * History of hyperthyroidism not caused by Graves' disease (eg. toxic adenoma, or toxic multinodular goiter) within 6 months before the screening visit * Pregnant or lactating women * Additional exclusion criteria are defined in the protocol

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Graves disease are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Graves disease hyperthyroidism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Graves disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    30 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinical Research Site

    NOT_YET_RECRUITING

    Tucson, Arizona, 85710, United States

  • Clinical Research Site

    NOT_YET_RECRUITING

    Raleigh, North Carolina, 27612, United States

  • Clinical Research Site

    NOT_YET_RECRUITING

    Dallas, Texas, 75246, United States

  • Site 100

    RECRUITING

    Amarillo, Texas, 79124, United States

  • Site 101

    RECRUITING

    Humble, Texas, 77346, United States

  • Site 103

    NOT_YET_RECRUITING

    Sacramento, California, 95817, United States

  • Site 105

    NOT_YET_RECRUITING

    Torrance, California, 90502, United States

  • Site 106

    RECRUITING

    Fort Worth, Texas, 76132, United States

  • Site 107

    RECRUITING

    Livonia, Michigan, 48152, United States

  • Site 108

    NOT_YET_RECRUITING

    Omaha, Nebraska, 68198, United States

  • Site 109

    RECRUITING

    Miami Lakes, Florida, 33016, United States

  • Site 110

    RECRUITING

    Houston, Texas, 77095, United States

  • Site 111

    NOT_YET_RECRUITING

    San Francisco, California, 94143, United States

  • Site 112

    RECRUITING

    Gilbert, Arizona, 85297, United States

  • Site 115

    RECRUITING

    Palm Harbor, Florida, 34684, United States

  • Site 116

    RECRUITING

    San Antonio, Texas, 78233, United States

  • Site 117

    RECRUITING

    Conroe, Texas, 77384, United States

  • Site 118

    RECRUITING

    Macon, Georgia, 31210, United States

  • Site 120

    RECRUITING

    Orchard Park, New York, 14127, United States

  • Site 121

    RECRUITING

    La Mesa, California, 91942, United States

  • Site 122

    RECRUITING

    Bowling Green, Kentucky, 42103, United States

  • Site 123

    NOT_YET_RECRUITING

    Sarasota, Florida, 34239, United States

  • Site 124

    NOT_YET_RECRUITING

    Sayre, Pennsylvania, 18840, United States

  • Site 126

    RECRUITING

    Flint, Michigan, 48532, United States

  • Site 127

    NOT_YET_RECRUITING

    El Paso, Texas, 79935, United States

  • Site 128

    RECRUITING

    Edinburg, Texas, 78539, United States

  • Site 129

    RECRUITING

    Niagara Falls, New York, 14304, United States

  • Site 130

    NOT_YET_RECRUITING

    Phoenix, Arizona, 85006, United States

  • Site 150

    NOT_YET_RECRUITING

    Melbourne N., Victoria, 3051, Australia

  • Site 151

    NOT_YET_RECRUITING

    East Melbourne, Victoria, 3002, Australia

More trials for these conditions

Other studies related to the condition(s) this trial covers.